Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer Ingelheim’s long acting beta-adrenergic agonist for chronic obstructive pulmonary disease will have to overcome LABA class issues in asthma at an advisory committee in January. The drug is up first for single-agent approval, but it is meant to be half of a combination therapy with the blockbuster treatment Spiriva.

You may also be interested in...

Boehringer’s Olodaterol Gains Advisory Committee Support, But May See Indication Clarified

FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 15-1 that efficacy and safety had been shown, but said the label should not imply it is a treatment for chronic bronchitis and emphysema, just airway obstruction in those conditions, as well as COPD.

BI’s Olodaterol Wants Novel Exercise Claims In COPD

Proposed claims for Striverdi Respimat include improved exercise tolerance and increased inspiratory capacity, but FDA has no clear regulatory pathway for them.

Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva

The company is borrowing a page, and a law firm, from GlaxoSmithKline’s 2009 citizen petition asking FDA to impose conditions on generic Advair.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts